Cargando…
Combined everolimus and endocrine therapy in advanced HR-positive, HER2-negative Chinese breast cancer patients: a retrospective study
BACKGROUND: Everolimus (EVE) is an inhibitor of the mammalian target of rapamycin (mTOR) pathway, and it is approved for the treatment of advanced breast cancer (ABC). However, there is still little real-world data on using EVE in Chinese breast cancer patients. We retrospectively analyzed real-worl...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8422157/ https://www.ncbi.nlm.nih.gov/pubmed/34532471 http://dx.doi.org/10.21037/atm-21-3840 |
_version_ | 1783749232614703104 |
---|---|
author | Shen, Xia-Bo Li, Guang-Liang Zheng, Ya-Bing Chen, Zhan-Hong Cao, Wen-Ming Wang, Xiao-Jia Shao, Xi-Ying |
author_facet | Shen, Xia-Bo Li, Guang-Liang Zheng, Ya-Bing Chen, Zhan-Hong Cao, Wen-Ming Wang, Xiao-Jia Shao, Xi-Ying |
author_sort | Shen, Xia-Bo |
collection | PubMed |
description | BACKGROUND: Everolimus (EVE) is an inhibitor of the mammalian target of rapamycin (mTOR) pathway, and it is approved for the treatment of advanced breast cancer (ABC). However, there is still little real-world data on using EVE in Chinese breast cancer patients. We retrospectively analyzed real-world data to determine the factors affecting EVE treatment efficacy and patient outcomes. METHODS: We retrospectively collected the treatment information of ABC patients treated with EVE from 2013 to 2020 in Zhejiang Cancer Hospital. Kaplan-Meier analysis and Cox regression methods were used to calculate and compare the progression-free survival (PFS), and identify the factors associated with EVE treatment efficacy. RESULTS: The study finally enrolled 84 patients meeting the requirement; the median PFS in all 84 patients was 6.87 months. Multivariate analysis showed that liver metastasis [hazard ratio, 1.69; 95% confidence interval (CI), 1.00–2.84; P=0.049], and brain metastasis (hazard ratio, 2.65; 95% CI, 1.07–6.58; P=0.036) were independent risk factors. Subgroup analyses demonstrated EVE + fulvestrant (FUL) was not superior to EVE + aromatase inhibitors (AIs) for PFS (5.77 vs. 7.97 months, P=0.0735). Furthermore, it showed EVE + AI was superior to EVE + FUL in some subgroups: postmenopausal group (hazard ratio, 0.50; 95% CI, 0.26–0.98); without bone metastasis group (hazard ratio, 0.22; 95% CI, 0.06–0.80); visceral disease group (hazard ratio, 0.37; 95% CI, 0.20–0.69). CONCLUSIONS: EVE combined with endocrine therapy is an effective treatment option for Chinese patients with hormone-receptor-positive (HR+), human epidermal growth factor receptor-2-negative (HER2−) breast cancer, although EVE + FUL was not superior to EVE + AI. Liver metastasis and brain metastasis were independent risk factors for successful EVE + endocrine therapy. |
format | Online Article Text |
id | pubmed-8422157 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | AME Publishing Company |
record_format | MEDLINE/PubMed |
spelling | pubmed-84221572021-09-15 Combined everolimus and endocrine therapy in advanced HR-positive, HER2-negative Chinese breast cancer patients: a retrospective study Shen, Xia-Bo Li, Guang-Liang Zheng, Ya-Bing Chen, Zhan-Hong Cao, Wen-Ming Wang, Xiao-Jia Shao, Xi-Ying Ann Transl Med Original Article BACKGROUND: Everolimus (EVE) is an inhibitor of the mammalian target of rapamycin (mTOR) pathway, and it is approved for the treatment of advanced breast cancer (ABC). However, there is still little real-world data on using EVE in Chinese breast cancer patients. We retrospectively analyzed real-world data to determine the factors affecting EVE treatment efficacy and patient outcomes. METHODS: We retrospectively collected the treatment information of ABC patients treated with EVE from 2013 to 2020 in Zhejiang Cancer Hospital. Kaplan-Meier analysis and Cox regression methods were used to calculate and compare the progression-free survival (PFS), and identify the factors associated with EVE treatment efficacy. RESULTS: The study finally enrolled 84 patients meeting the requirement; the median PFS in all 84 patients was 6.87 months. Multivariate analysis showed that liver metastasis [hazard ratio, 1.69; 95% confidence interval (CI), 1.00–2.84; P=0.049], and brain metastasis (hazard ratio, 2.65; 95% CI, 1.07–6.58; P=0.036) were independent risk factors. Subgroup analyses demonstrated EVE + fulvestrant (FUL) was not superior to EVE + aromatase inhibitors (AIs) for PFS (5.77 vs. 7.97 months, P=0.0735). Furthermore, it showed EVE + AI was superior to EVE + FUL in some subgroups: postmenopausal group (hazard ratio, 0.50; 95% CI, 0.26–0.98); without bone metastasis group (hazard ratio, 0.22; 95% CI, 0.06–0.80); visceral disease group (hazard ratio, 0.37; 95% CI, 0.20–0.69). CONCLUSIONS: EVE combined with endocrine therapy is an effective treatment option for Chinese patients with hormone-receptor-positive (HR+), human epidermal growth factor receptor-2-negative (HER2−) breast cancer, although EVE + FUL was not superior to EVE + AI. Liver metastasis and brain metastasis were independent risk factors for successful EVE + endocrine therapy. AME Publishing Company 2021-08 /pmc/articles/PMC8422157/ /pubmed/34532471 http://dx.doi.org/10.21037/atm-21-3840 Text en 2021 Annals of Translational Medicine. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) . |
spellingShingle | Original Article Shen, Xia-Bo Li, Guang-Liang Zheng, Ya-Bing Chen, Zhan-Hong Cao, Wen-Ming Wang, Xiao-Jia Shao, Xi-Ying Combined everolimus and endocrine therapy in advanced HR-positive, HER2-negative Chinese breast cancer patients: a retrospective study |
title | Combined everolimus and endocrine therapy in advanced HR-positive, HER2-negative Chinese breast cancer patients: a retrospective study |
title_full | Combined everolimus and endocrine therapy in advanced HR-positive, HER2-negative Chinese breast cancer patients: a retrospective study |
title_fullStr | Combined everolimus and endocrine therapy in advanced HR-positive, HER2-negative Chinese breast cancer patients: a retrospective study |
title_full_unstemmed | Combined everolimus and endocrine therapy in advanced HR-positive, HER2-negative Chinese breast cancer patients: a retrospective study |
title_short | Combined everolimus and endocrine therapy in advanced HR-positive, HER2-negative Chinese breast cancer patients: a retrospective study |
title_sort | combined everolimus and endocrine therapy in advanced hr-positive, her2-negative chinese breast cancer patients: a retrospective study |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8422157/ https://www.ncbi.nlm.nih.gov/pubmed/34532471 http://dx.doi.org/10.21037/atm-21-3840 |
work_keys_str_mv | AT shenxiabo combinedeverolimusandendocrinetherapyinadvancedhrpositiveher2negativechinesebreastcancerpatientsaretrospectivestudy AT liguangliang combinedeverolimusandendocrinetherapyinadvancedhrpositiveher2negativechinesebreastcancerpatientsaretrospectivestudy AT zhengyabing combinedeverolimusandendocrinetherapyinadvancedhrpositiveher2negativechinesebreastcancerpatientsaretrospectivestudy AT chenzhanhong combinedeverolimusandendocrinetherapyinadvancedhrpositiveher2negativechinesebreastcancerpatientsaretrospectivestudy AT caowenming combinedeverolimusandendocrinetherapyinadvancedhrpositiveher2negativechinesebreastcancerpatientsaretrospectivestudy AT wangxiaojia combinedeverolimusandendocrinetherapyinadvancedhrpositiveher2negativechinesebreastcancerpatientsaretrospectivestudy AT shaoxiying combinedeverolimusandendocrinetherapyinadvancedhrpositiveher2negativechinesebreastcancerpatientsaretrospectivestudy |